BioSig Technologies Inc Financials

BSGM

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows BioSig Technologies Inc (BSGM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Neutral

4/9

BioSig Technologies Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.46x

For every $1 of reported earnings, BioSig Technologies Inc generates $0.46 in operating cash flow (-$4.8M OCF vs -$10.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1169.3x

BioSig Technologies Inc earns $-1169.3 in operating income for every $1 of interest expense (-$12.9M vs $11K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$40K

YoY+122.2%

BioSig Technologies Inc generated $40K in revenue in fiscal year 2024. This represents an increase of 122.2% from the prior year.

EBITDA

-$12.7M

YoY+55.0%

BioSig Technologies Inc's EBITDA was -$12.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.0% from the prior year.

Free Cash Flow

N/A

Net Income

-$10.3M

YoY+64.4%

BioSig Technologies Inc reported -$10.3M in net income in fiscal year 2024. This represents an increase of 64.4% from the prior year.

EPS (Diluted)

$-0.75

YoY+81.0%

BioSig Technologies Inc earned $-0.75 per diluted share (EPS) in fiscal year 2024. This represents an increase of 81.0% from the prior year.

Cash & Debt

$142K

YoY-29.0%

5Y CAGR-58.9%

10Y CAGR-5.1%

BioSig Technologies Inc held $142K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

17M

YoY+90.7%

BioSig Technologies Inc had 17M shares outstanding in fiscal year 2024. This represents an increase of 90.7% from the prior year.

Gross Margin

N/A

Operating Margin

-32155.0%

YoY+126245.0pp

BioSig Technologies Inc's operating margin was -32155.0% in fiscal year 2024, reflecting core business profitability. This is up 126245.0 percentage points from the prior year.

Net Margin

-25825.0%

YoY+135513.9pp

BioSig Technologies Inc's net profit margin was -25825.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 135513.9 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$832K

YoY-83.7%

5Y CAGR-38.9%

10Y CAGR-5.8%

BioSig Technologies Inc invested $832K in research and development in fiscal year 2024. This represents a decrease of 83.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BSGM Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$40K+122.2%	$18K-93.7%	$286K-35.1%	$441K	$0	N/A
Cost of Revenue	N/A	N/A	$57K-71.4%	$199K	$0	N/A
Gross Profit	N/A	$18K-92.1%	$229K-5.4%	$242K	$0	N/A
R&D Expenses	$832K-83.7%	$5.1M-12.5%	$5.8M+3.9%	$5.6M-69.1%	$18.1M+86.2%	$9.7M
SG&A Expenses	$11.6M-49.6%	$23.1M+7.9%	$21.4M-23.2%	$27.9M-32.0%	$41.0M+65.1%	$24.8M
Operating Income	-$12.9M+54.9%	-$28.5M-4.6%	-$27.3M+18.4%	-$33.4M+43.5%	-$59.2M-71.0%	-$34.6M
Interest Expense	-$11K-222.2%	$9K+200.0%	$3K+50.0%	$2K-95.6%	$45K-66.2%	$133K
Income Tax	$0	N/A	$0	$0	$0	$0
Net Income	-$10.3M+64.4%	-$29.0M-7.4%	-$27.1M+15.2%	-$31.9M+38.9%	-$52.2M-53.3%	-$34.1M
EPS (Diluted)	$-0.75+81.0%	$-3.95+37.6%	$-6.33	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	$13K-7.1%	$14K+16.7%	$12K+1100.0%	$1K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1K
R&D Expenses	$6K-68.4%	$19K+216.7%	$6K-96.2%	$156K-54.4%	$342K+43.7%	$238K-79.8%	$1.2M+2.7%	$1.1M
SG&A Expenses	$4.6M-76.7%	$19.8M+569.3%	$3.0M+7.0%	$2.8M-43.8%	$4.9M+70.5%	$2.9M-41.3%	$4.9M+74.4%	$2.8M
Operating Income	-$6.1M+70.0%	-$20.4M-582.5%	-$3.0M-1.2%	-$3.0M+44.3%	-$5.3M-54.0%	-$3.4M+44.3%	-$6.2M-52.2%	-$4.1M
Interest Expense	-$10K-176.9%	$13K	N/A	N/A	-$5K-66.7%	-$3K-400.0%	$1K0.0%	$1K
Income Tax	-$765K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$15.6M+23.5%	-$20.4M-624.5%	-$2.8M-46.9%	-$1.9M+51.1%	-$3.9M-15.1%	-$3.4M+43.8%	-$6.0M-32.5%	-$4.6M
EPS (Diluted)	$-0.47+36.5%	$-0.74-428.6%	$-0.14-16.7%	$-0.12+60.0%	$-0.30+16.7%	$-0.36+36.8%	$-0.57+6.6%	$-0.61

BSGM Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$842K-53.2%	$1.8M-56.3%	$4.1M-73.5%	$15.5M-48.9%	$30.4M+113.7%	$14.2M
Current Assets	$344K-34.8%	$528K-53.2%	$1.1M-91.9%	$13.9M-52.6%	$29.3M+128.7%	$12.8M
Cash & Equivalents	$142K-29.0%	$200K-50.0%	$400K-96.6%	$11.7M-58.6%	$28.3M+133.5%	$12.1M
Inventory	N/A	$2.0M+488.1%	$336K-82.1%	$1.9M+144.9%	$768K+32.9%	$578K
Accounts Receivable	$109K+354.2%	$24K+166.7%	$9K	$0	$0	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.3M-51.7%	$4.7M+26.2%	$3.7M+25.7%	$3.0M-42.2%	$5.1M+66.4%	$3.1M
Current Liabilities	$2.3M-50.6%	$4.6M+40.5%	$3.3M+26.6%	$2.6M-49.6%	$5.1M+151.6%	$2.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.5M+48.8%	-$3.0M-1064.2%	$313K-97.4%	$12.2M-49.8%	$24.4M+118.6%	$11.1M
Retained Earnings	-$255.3M-4.2%	-$245.0M-13.4%	-$216.0M-14.3%	-$188.9M-20.3%	-$157.0M-49.8%	-$104.8M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$130.5M+19.0%	$109.7M+2383.5%	$4.4M+424.7%	$842K-72.9%	$3.1M+95.5%	$1.6M-11.6%	$1.8M-43.0%	$3.2M
Current Assets	$15.0M+399.6%	$3.0M-24.7%	$4.0M+1058.7%	$344K-85.6%	$2.4M+222.4%	$740K+40.2%	$528K-49.8%	$1.1M
Cash & Equivalents	$11.0M+291.7%	$2.8M-24.3%	$3.7M+2524.6%	$142K-93.3%	$2.1M+405.8%	$416K+108.0%	$200K-50.0%	$400K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$2.0M+802.3%	$219K
Accounts Receivable	N/A	N/A	$109K0.0%	$109K+101.9%	$54K+285.7%	$14K-41.7%	$24K+71.4%	$14K
Goodwill	$69.9M+19.1%	$58.7M	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$137.3M+21.3%	$113.2M+6642.1%	$1.7M-25.8%	$2.3M-24.3%	$3.0M-48.4%	$5.8M+23.6%	$4.7M+14.2%	$4.1M
Current Liabilities	$125.6M+11.0%	$113.2M+6642.1%	$1.7M-25.8%	$2.3M-23.9%	$3.0M-43.1%	$5.2M+14.2%	$4.6M+17.2%	$3.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$7.0M-92.4%	-$3.6M-238.8%	$2.6M+268.7%	-$1.5M-25633.3%	-$6K+99.9%	-$4.3M-43.2%	-$3.0M-160.2%	-$1.2M
Retained Earnings	-$294.1M-5.6%	-$278.5M-7.9%	-$258.2M-1.1%	-$255.3M-1.2%	-$252.3M-1.6%	-$248.4M-1.4%	-$245.0M-2.5%	-$239.0M

BSGM Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$4.8M+72.5%	-$17.3M+20.2%	-$21.7M+17.8%	-$26.4M+0.8%	-$26.6M-71.8%	-$15.5M
Capital Expenditures	N/A	$186K+10.7%	$168K-69.0%	$542K+523.0%	$87K-50.8%	$177K
Free Cash Flow	N/A	-$17.5M+20.0%	-$21.9M+18.8%	-$26.9M-0.9%	-$26.7M-70.4%	-$15.7M
Investing Cash Flow	N/A	-$186K-10.7%	-$168K+69.0%	-$542K-523.0%	-$87K+69.5%	-$285K
Financing Cash Flow	$4.7M-72.8%	$17.3M+64.0%	$10.6M+2.3%	$10.3M-75.9%	$42.8M+82.9%	$23.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$5.0M-293.0%	-$1.3M-14.6%	-$1.1M-135.2%	-$474K+68.0%	-$1.5M-12.7%	-$1.3M+55.3%	-$2.9M+23.1%	-$3.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$4K-93.3%	$60K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$2.9M+24.2%	-$3.9M
Investing Cash Flow	-$145K	N/A	N/A	N/A	N/A	N/A	-$4K+93.3%	-$60K
Financing Cash Flow	$13.4M	$0-100.0%	$4.7M+469900.0%	$1K-100.0%	$3.2M+105.8%	$1.5M-43.9%	$2.7M-9.2%	$3.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BSGM Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	100.0%+19.9pp	80.1%+25.2pp	54.9%	N/A	N/A
Operating Margin	-32155.0%+126245.0pp	-158400.0%-148866.8pp	-9533.2%-1957.0pp	-7576.2%	N/A	N/A
Net Margin	-25825.0%+135513.9pp	-161338.9%-151880.1pp	-9458.7%-2221.3pp	-7237.4%	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-1226.8%+388.3pp	-1615.2%-957.0pp	-658.2%-452.5pp	-205.7%-33.8pp	-171.8%+67.7pp	-239.5%
Current Ratio	0.15+0.0	0.12-0.2	0.35-5.0	5.39-0.3	5.74-0.6	6.32
Debt-to-Equity	-1.47+0.1	-1.55-13.4	11.86+11.6	0.24+0.0	0.21-0.1	0.28
FCF Margin	N/A	-97216.7%-89568.8pp	-7647.9%-1538.8pp	-6109.1%	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%
Operating Margin	N/A	N/A	N/A	N/A	-40707.7%-16157.7pp	-24550.0%+26841.7pp	-51391.7%+353708.3pp	-405100.0%
Net Margin	N/A	N/A	N/A	N/A	-30115.4%-5815.4pp	-24300.0%+26108.3pp	-50408.3%+406291.7pp	-456700.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-11.9%+6.6pp	-18.6%+45.1pp	-63.6%+71.3pp	-135.0%-9.0pp	-126.0%+88.1pp	-214.1%+122.3pp	-336.4%-191.6pp	-144.8%
Current Ratio	0.12+0.1	0.03-2.3	2.37+2.2	0.15-0.6	0.80+0.7	0.14+0.0	0.12-0.2	0.27
Debt-to-Equity	-19.73+11.6	-31.30-31.9	0.64+2.1	-1.47+497.0	-498.50-497.2	-1.34+0.2	-1.55+2.0	-3.54
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-24550.0%+364250.0pp	-388800.0%

Note: Shareholder equity is negative (-$1.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.15), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Cvrx, Inc. CVRX

$130.2M

908 Devices Inc. MASS

$234.9M

Outset Medical, Inc. OM

$62.1M

TriSalus Life Sciences Inc. TLSI

$243.3M

Monogram Orthopaedics Inc MGRM

$243.8M

Frequently Asked Questions

What is BioSig Technologies Inc's annual revenue?

BioSig Technologies Inc (BSGM) reported $40K in total revenue for fiscal year 2024. This represents a 122.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BioSig Technologies Inc's revenue growing?

BioSig Technologies Inc (BSGM) revenue grew by 122.2% year-over-year, from $18K to $40K in fiscal year 2024.

Is BioSig Technologies Inc profitable?

No, BioSig Technologies Inc (BSGM) reported a net income of -$10.3M in fiscal year 2024, with a net profit margin of -25825.0%.

What is BioSig Technologies Inc's earnings per share (EPS)?

BioSig Technologies Inc (BSGM) reported diluted earnings per share of $-0.75 for fiscal year 2024. This represents a 81.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is BioSig Technologies Inc's EBITDA?

BioSig Technologies Inc (BSGM) had EBITDA of -$12.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is BioSig Technologies Inc's operating margin?

BioSig Technologies Inc (BSGM) had an operating margin of -32155.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is BioSig Technologies Inc's net profit margin?

BioSig Technologies Inc (BSGM) had a net profit margin of -25825.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is BioSig Technologies Inc's operating cash flow?

BioSig Technologies Inc (BSGM) generated -$4.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are BioSig Technologies Inc's total assets?

BioSig Technologies Inc (BSGM) had $842K in total assets as of fiscal year 2024, including both current and long-term assets.

How much does BioSig Technologies Inc spend on research and development?

BioSig Technologies Inc (BSGM) invested $832K in research and development during fiscal year 2024.

How many shares does BioSig Technologies Inc have outstanding?

BioSig Technologies Inc (BSGM) had 17M shares outstanding as of fiscal year 2024.

What is BioSig Technologies Inc's current ratio?

BioSig Technologies Inc (BSGM) had a current ratio of 0.15 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is BioSig Technologies Inc's debt-to-equity ratio?

BioSig Technologies Inc (BSGM) had a debt-to-equity ratio of -1.47 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BioSig Technologies Inc's return on assets (ROA)?

BioSig Technologies Inc (BSGM) had a return on assets of -1226.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is BioSig Technologies Inc's cash runway?

Based on fiscal year 2024 data, BioSig Technologies Inc (BSGM) had $142K in cash against an annual operating cash burn of $4.8M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is BioSig Technologies Inc's debt-to-equity ratio negative or unusual?

BioSig Technologies Inc (BSGM) has negative shareholder equity of -$1.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is BioSig Technologies Inc's Piotroski F-Score?

BioSig Technologies Inc (BSGM) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BioSig Technologies Inc's earnings high quality?

BioSig Technologies Inc (BSGM) has an earnings quality ratio of 0.46x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BioSig Technologies Inc cover its interest payments?

BioSig Technologies Inc (BSGM) has an interest coverage ratio of -1169.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.